Key facts
- It has raised $66.1M; the latest was Later Stage VC ($60.0M) in Oct 2024.
- Notable investors include Noshaq, EQT Life Sciences, SambrInvest, Société Fédérale de Participations et d'Investissement, Directorate General for Economy — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for atbtherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for atbtherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About atbtherapeutics
Developer of antibody-based targeted therapy from plant cells designed to provide novel therapeutic treatment for patients with hard-to-treat cancer. The company develops antibodies with a new class of immunotherapy which is a biologic format aimed at expanding the therapeutic window for treatment, enabling healthcare practitioners to use the combination of a new bioprocess with novel targeted therapies to help cancer patients.
- Sector
- Healthcare
- HQ
- Aye, Belgium
- Founded
- 2017
- Employees
- 24
- Website
- atbtherapeutics.com/
- Ownership
- Privately Held (backing)
atbtherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in atbtherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on atbtherapeutics in its N-PORT filings yet. We sweep new filings monthly.